K.J. Harrison & Partners Inc lowered its position in Pfizer Inc. (NYSE:PFE) by 46.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,480 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the period. K.J. Harrison & Partners Inc’s holdings in Pfizer were worth $838,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after purchasing an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after purchasing an additional 2,028,313 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Pfizer by 3.2% in the third quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after purchasing an additional 1,085,437 shares in the last quarter. Finally, LSV Asset Management lifted its holdings in shares of Pfizer by 0.6% in the second quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock valued at $1,117,726,000 after purchasing an additional 199,100 shares in the last quarter. Institutional investors and hedge funds own 69.75% of the company’s stock.

Shares of Pfizer Inc. (NYSE PFE) opened at $36.86 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $219,710.00, a P/E ratio of 22.61, a P/E/G ratio of 2.45 and a beta of 1.01. Pfizer Inc. has a 52-week low of $30.90 and a 52-week high of $37.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s revenue was up .9% on a year-over-year basis. During the same period last year, the business posted $0.61 earnings per share. research analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

Pfizer announced that its board has initiated a share buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is currently 78.53%.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock valued at $1,065,220 over the last three months. Company insiders own 0.06% of the company’s stock.

A number of research analysts have recently weighed in on the company. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. JPMorgan Chase & Co. set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Jefferies Group set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. Nord/LB restated a “neutral” rating on shares of Pfizer in a report on Tuesday. Finally, Morgan Stanley set a $41.00 target price on Pfizer and gave the company a “buy” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $38.88.

TRADEMARK VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/k-j-harrison-partners-inc-sells-20000-shares-of-pfizer-inc-pfe/1796983.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.